%0 Journal Article
%A Tagarro, Alfredo
%A Domínguez-Rodríguez, Sara
%A Mesa, Juan Miguel
%A Epalza, Cristina
%A Grasa, Carlos
%A Iglesias-Bouzas, María Isabel
%A Fernández-Cooke, Elisa
%A Calvo, Cristina
%A Villaverde, Serena
%A Torres-Fernández, David
%A Méndez-Echevarria, Ana
%A Leoz, Inés
%A Fernández-Pascual, María
%A Saavedra-Lozano, Jesús
%A Soto, Beatriz
%A Aguilera-Alonso, David
%A Rivière, Jacques G
%A Fumadó, Victoria
%A Martínez-Campos, Leticia
%A Vivanco, Ana
%A Pilar-Orive, Francisco Javier
%A Alcalá, Pedro
%A Ruiz, Beatriz
%A López-Machín, Ana
%A Oltra, Manuel
%A Moraleda, Cinta
%A EPICO Working Group
%T Treatments for multi-system inflammatory syndrome in children - discharge, fever, and second-line therapies.
%D 2022
%U http://hdl.handle.net/10668/20197
%X Scarce evidence exists about the best treatment for multi-system inflammatory syndrome (MIS-C). We analyzed the effects of steroids, intravenous immunoglobulin (IVIG), and their combination on the probability of discharge over time, the probability of switching to second-line treatment over time, and the persistence of fever 2 days after treatment. We did a retrospective study to investigate the effect of different treatments on children with MIS-C from 1 March 2020 to 1 June 2021. We estimated the time-to-event probability using a Cox model weighted by propensity score to balance the baseline characteristics. Thirty of 132 (22.7%) patients were initially treated with steroids alone, 29/132 (21.9%) with IVIG alone, and 73/132 (55%) with IVIG plus steroids. The probability of early discharge was higher with IVIG than with IVIG plus steroids (hazard ratio [HR] 1.65, 95% CI 1.11-2.45, p = 0.013), but with a higher probability of needing second-line therapy compared to IVIG plus steroids (HR 3.05, 95% CI 1.12-8.25, p = 0.028). Patients on IVIG had a higher likelihood of persistent fever than patients on steroids (odds ratio [OR] 4.23, 95% CI 1.43-13.5, p = 0.011) or on IVIG plus steroids (OR 4.4, 95% CI 2.05-9.82, p 
%K COVID-19
%K Children
%K MIS-C
%K SARS-CoV-2
%~